A Smart, Shakespearean Perspective on Missing the Mark
“Missed it by that much …” That was one of the catchphrases from the farcical spy situation comedy “Get Smart,” a Mel Brooks brainchild. Maxwell Smart, Agent 86, frequently uttered those…
A Smart, Shakespearean Perspective on Missing the Mark
First Patient Enrolled in Phase 2a Trial of Engensis
The first patient has been enrolled in a Phase 2a clinical trial investigating Helixmith’s gene therapy Engensis (VM202) for the treatment of amyotrophic lateral sclerosis (ALS), the company announced. The REViVALS-1A study (NCT04632225) intends to recruit 18 patients across four clinical sites in the U.S. Enrollment is open…
How I Live With Gravity, Coincidence, and ALS
I’ll admit that during my high school days, when our studies turned toward physics, I didn’t pay much attention. Gravity, the invisible force that keeps us on the ground and makes things fall, seemed so bo-ring. But in 2010, when I was diagnosed with ALS, the condition put me through…
#MDA2021 – Rare WWOX Mutations in Patients Affect Mitochondria of Cells
Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference. Variants in the WWOX gene may contribute to the development of amyotrophic lateral sclerosis (ALS)…
HEALEY Trial Reaches 50% Enrollment for First 3 Regimens
The HEALEY ALS platform trial, which is evaluating the safety and efficacy of several potential treatments for amyotrophic lateral sclerosis (ALS), has passed the 50% participant enrollment target for its first three regimens. The investigational treatments are UCB’s zilucoplan, Biohaven Pharmaceuticals’ verdiperstat, and Clene Nanomedicine’s CNM-Au8. A fourth candidate…
Mitsubishi Tanabe Establishes New US Research Facility
Mitsubishi Tanabe Pharma Corporation (MTPC) is opening a new research site in the Boston area dedicated to discovering new therapeutic targets in amyotrophic lateral sclerosis (ALS) and other diseases of the central nervous system. Located in the SmartLabs biotechnology hub in Cambridge, Massachusetts, the company’s NeuroDiscovery Lab is scheduled…
Life With ALS Is Hard, and Sometimes the Little Things Are Too Much
Sometimes little things push me over the edge. One morning last week, I was already cranky because I had burnt the oatmeal. The smell followed me, lingering in my hair as I drove the kids to school. After I dropped them off, I stopped by a store on the way…
Amylyx Planning to Ask Health Canada to Approve AMX0035 to Treat ALS
Amylyx Pharmaceuticals plans to soon apply to Health Canada, requesting approval of oral AMX0035 to treat amyotrophic lateral sclerosis (ALS) based on the findings of the CENTAUR clinical trial. The company will also explore options for early access to the therapy for patients in the country. One possibly route…
Peaceful Reflections From an Empty Bucket
“‘Cause I got a peaceful, easy feelin’, And I know you won’t let me down, ‘Cause I’m already standin’ On the ground.” Those lyrics by Jack Tempchin, sung by the Eagles on their…
Partnership Gets Communication Devices to Mississippi ALS Patients
Under a new local partnership, Mississippi residents who have amyotrophic lateral sclerosis (ALS) will have free access to communication devices and training. The program is a collaboration between speech-language graduate students at the Mississippi University for Women’s Speech & Hearing Center and the ALS Association Louisiana-Mississippi Chapter.
Recent Posts
- Just what does coping mean when you’re living with ALS?
- ATH-1105 experimental therapy found safe in healthy adults: Trial
- Adding low-dose IL-2 to riluzole may improve survival in ALS
- Bacteria mix to aid gut microbiome may slow ALS progression
- Neuronata-R improved function, survival in slow-progressing ALS